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Abstract
Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and
middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is
associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised
exclusively anti-estrogen and related hormonal therapies. These treatments, however, have not been
proven effective. In this article, we discuss new findings regarding the molecular mechanisms involved
in the regulation of LAM cell growth, which may offer opportunities to develop effective and targeted
therapeutic agents.
Introduction and context
Lymphangioleiomyomatosis (LAM) is a multisystem
disease affecting predominantly premenopausal and
middle-aged women and is characterized by proliferation
of abnormal smooth muscle-like cells (LAM cells) [1].
LAM is associated with cystic lung destruction, fluid-filled
cystic tumors in the axial lymphatics (for example,
lymphangioleiomyomas), and abdominal tumors (for
example, angiomyolipomas), primarily in the kidneys,
comprising adipocytes, vascular structures, and smooth
muscle cells [1]. LAM occursin about one-third of women
with tuberous sclerosis complex (TSC), an autosomal
dominant disorder, with variable penetrance. TSC occurs
in 1 of 5800 live births [2], results from mutations
in the TSC1 or TSC2 genes [2], and is characterized by
hamartoma-like tumor growths in various organs, cere-
bral calcifications, seizures, and mental retardation.
Sporadic LAM is a relatively uncommon disease, with a
prevalence that has been estimated at 1-2.6 per million
women [3].
The tumor suppressor genes, TSC1 and TSC2, have been
implicated in the etiology of sporadic LAM because
mutations and loss of heterozygosity in the TSC genes
have been detected in LAM cells [4,5]. TSC1 encodes
hamartin, a protein that plays a role in the reorganiza-
tion of the actin cytoskeleton, and TSC2 encodes tuberin,
a protein with roles in cell growth and proliferation [4,5].
LAM presents with dyspnea, pneumothorax, chy-
lothorax, ascites, or angiomyolipoma-derived abdom-
inal hemorrhage [1]. Imaging studies show numerous
thin-walled cysts throughout the lungs, angiomyolipo-
mas, and lymphangioleiomyomas (Figure 1). Pulmon-
ary function tests show reduced expiratory flow rates or
lung diffusion capacity or both [1].
Because LAM is predominantly a disease of premeno-
pausal women and may worsen during pregnancy [6] or
following the administration of estrogens [7], hormonal
manipulations have been employed in its treatment.
However, no controlled studies have been undertaken
to determine their efficacy. In a retrospective study, we
found no difference in disease progression between
patients treated with or without progesterone [8].
Suppression of ovarian function, either by oophorect-
omy or gonadotropin-releasing hormone (GnRH) ana-
logs, also did not appear to benefit patients [8,9]. A trend
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menopausal patients has been noted [8]. Overall, at
present, treatment of LAM involves supportive care,
management of complications (for example, pneu-
mothorax, pleural effusions, and ascites), bronchodila-
tors (as needed for asthma-like symptoms), oxygen
therapy, and (in cases of respiratory failure) lung
transplantation.
Recent advances
Inhibitors of mammalian target of rapamycin
TSC1 and TSC2 are tumor suppressor genes that encode
hamartin and tuberin, respectively [10,11]. Hamartin and
tuberin may have individual functions, but they also
interact to form a cytosolic complex. Hamartin functions
in the reorganization of the actin cytoskeleton by
interacting with the ezrin-radixin-moesin family of
proteins [12]. Tuberin has roles in pathways control-
ling cell growth and proliferation (Figure 2) [13]. It is
described as a negative regulator of cell cycle progression
since the loss of tuberin shortens the G1 phase of the cell
cycle. Tuberin binds p27Kip1, a cyclin-dependent kinase
(CDK) inhibitor, preventing its degradation and leading
to inhibition of the cell cycle. In the absence of tuberin,
p27 becomes mislocalized in the cytoplasm, allowing the
cell cycle to progress [13].
The TSC1/2 complex acts upstream of the intracellular
serine/threonine kinase mammalian target of rapamycin
(mTOR) and mediates growth factor, energy, and stress
signals, thereby regulating cell growth and proliferation.
There are two different complexes that contain mTOR:
mTORC1, which contains raptor (regulatory associated
protein of mTOR), and mTORC2, which contains rictor
(rapamycin-insensitive companion of mTOR) [14-16].
TSC1/2 positively regulates mTORC2, leading to phos-
phorylation and activation of protein kinase B (Akt)
[17,18], while it negatively regulates mTORC1. In the
presence of growth factors, both the mitogen-activated
protein kinase (MAPK) and insulin signaling pathways
can be activated, resulting in inhibition of TSC1/2
through phosphorylation of TSC2 by p90 ribosomal
S6 kinase (RSK), extracellular signal-regulated kinase
(ERK1/2), or Akt [19-22]. TSC2 acts as a GTPase-
activating protein (GAP) for Ras homolog enriched in
brain (Rheb), promoting the formation of inactive Rheb-
GDP from the active Rheb-GTP [23-25]. Inhibition of
TSC1/2 by growth factor stimulation inhibits the GAP
activity and allows accumulation of active Rheb-GTP.
Rheb-GTP stimulates mTORC1, which phosphorylates
substrates such as ribosomal S6 kinases and eukaryotic
Figure 1. Computed tomography scans of patients with
lymphangioleiomyomatosis
(a) Numerous thin-walled cysts distributed throughout the lungs.
(b) A large lymphangioleiomyoma (arrow) located in the retroperitoneal
area surrounding the aorta (A) and inferior vena cava (IVC).
(c) Angiomyolipomas involving both kidneys.
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enhanced protein translation [26].
Both the MAPK and insulin signaling pathways can affect
mTORC1 without involving TSC1/2. RSK can phosphor-
ylate raptor of mTORC1 [27], thus promoting mTORC1
kinase activity directly. Akt phosphorylates PRAS40
(proline-rich Akt substrate of 40 kDa), an inhibitor of
mTORC1, and relieves this inhibition [28].
TSC1/2 also integrates signals indicating amino acid
levels and energy status, both of which are necessary to
Figure 2. TSC1/2 integrates multiple signals to control cell growth and proliferation
Growth factors stimulate the MAPK and insulin signaling pathways, leading to TSC2 phosphorylation and inactivation. TSC1/2 negatively regulates mTORC1
through its actions on Rheb, while it positively regulates mTORC2. The insulin signaling pathway can activate mTORC1 without going through TSC1/2 by Akt
phosphorylation of PRAS40, an inhibitor of mTORC1, thereby relieving the inhibition. Similarly, the MAPK signaling pathway can activate mTORC1 without going
through TSC1/2 via RSK phosphorylation of raptor, a component of the mTORC1 complex, leading to mTORC1 activation. Activation of mTORC1 leads to
protein translation and to a negative feedback loop on the activation of the insulin and MAPK signaling pathways. In the presence of amino acids, the Rag GTPase
heterodimers promote the localization of mTORC1 to cellular compartments containing Rheb, thereby promoting mTORC1 activation. In conditions of low
cellular energy or hypoxia, AMPK phosphorylates and activates TSC2, while hypoxia increases the transcription of REDD1, which also activates TSC2, leading to
inhibition of translation. TSC2 binds p27Kip1, a cyclin-dependent kinase inhibitor, stabilizing it and resulting in inhibition of cell cycle progression. Sirolimus, or
rapamycin, inhibits mTORC1, while CI-1040 is an MAPK/ERK inhibitor. Roscovitine is an inhibitor of CDK2. 4E-BP1, factor 4E-binding protein 1; Akt, protein
kinase B; AMPK, AMP-dependent protein kinase; CDK2, cyclin-dependent kinase 2; ERK1/2, extracellular signal-regulated kinase; MAPK, mitogen-activated
protein kinase; mTORC, mammalian target of rapamycin complex; PDK1, pyruvate dehydrogenase kinase, isozyme 1; PI3K, phosphoinositide 3-kinase; PRAS40,
proline-rich protein kinase B substrate of 40 kDa; Rag, Ras-related small GTP-binding protein; REDD1, regulated in the development and DNA damage
response 1; Rheb, Ras homolog enriched in brain; RSK, p90 ribosomal S6 kinase; S6K1, S6 kinase 1; TSC, tuberous sclerosis complex.
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levels of AMP (indicating energy stress), AMP-dependent
protein kinase (AMPK) phosphorylates and activates
TSC2, thereby inhibiting mTORC1 and translation [29].
Hypoxia can inhibit mTORC1 activity both by stimula-
tion of AMPK (as oxygen is necessary for the production
of ATP by oxidative phosphorylation) and by increasing
the transcription of REDD1 (regulated in development
and DNA damage response 1), which activates TSC2 [30].
Amino acids promote GTP binding by Rag (Ras-related
small GTP-binding protein)-GTPase heterodimers, which
bind raptor, promoting mTORC1 localization in cellular
compartments where Rheb is present. This allows
mTORC1 activation only when there are sufficient
amino acids to support translation [31].
Rapamycin, or sirolimus, forms a complex with FKBP-12
(FK506-binding protein-12) that binds and inhibits
mTORC1 [32]. mTORC1 is acutely inhibited by rapa-
mycin, whereas mTORC2 responds only to prolonged
rapamycin treatment and concentration [33-36]. Siroli-
mus decreased tumor size in a rat model of TSC with a
functionally null germline mutation of Tsc2, which
spontaneously develops renal cell carcinomas [37].
There were, however, rare persistent renal tumors,
which suggest some resistance to rapamycin. In patients
with angiomyolipomas, tumor size decreased by half
after 1 year of sirolimus therapy, while lung function was
improved in some patients [38]. Without sirolimus,
however, the angiolipomas regained size. A second
report suggests that sirolimus may inhibit the decline
in lung function rather than improve function [39].
A Multicenter International Lymphangioleiomyomatosis
Efficacy of Sirolimus Trial (University of Cincinnati
Medical Center, Cincinnati, OH, USA; Frank McCormack,
principal investigator) to examine the effect of rapamycin
on pulmonary function is in progress.
It has been found that, due to upregulation of receptor
tyrosine kinases, inhibition of mTORC1 results in the
activation of Akt [40-42]. Due to activation of the S6K
PI3K(phosphoinositide3-kinase)-Raspathway,mTORC1
inhibition also leads to the activation of the ERK/MAPK
cascade [43]. The activation of the Akt and ERK/MAPK
signaling pathways may partially explain why rapamycin
treatment has not beenfound to be completely successful.
Inhibition of the MAPK pathway along with use of
rapamycinhasbeenfoundtobemoreefficientatblocking
mouse Tsc2
−/− cell proliferation than either inhibitor
alone [44].
Estrogens
Several observations implicate estrogens in the patho-
genesis of LAM. Estradiol stimulated growth of human
angiomyolipoma TSC2
−/− cells [45] and pulmonary
metastasis of Tsc2
−/− Eker rat uterine leiomyoma-derived
smooth muscle (ELT3) cells in mice [46], which was
associated with activation of p42/44 MAPK. Estrogen
enhanced the survival and colonization of intravenously
injected Tsc 2
−/− cells in mice [46], an effect prevented by
the MAPK/ERK kinase (MEK) inhibitor CI-1040 [46].
Estrogen receptor activation also increased matrix
metalloproteinase (MMP)-2 activity of LAM cells, pro-
moting LAM cell invasiveness, and doxycycline, an
antibiotic with anti-MMP activity, inhibited this effect,
suggesting an estrogen-MMP-driven process in lung
destruction and LAM cell metastasis [47]. Finally,
estrogens accelerated growth of angiomyolipoma cells
in a xenograft tumor system [48]. These data suggest that
blockade of the MEK pathway and inhibition of MMP
production could be new potential approaches to the
treatment of LAM. Furthermore, anti-estrogen therapy
may have a role in LAM, but timing it to preclude LAM
cell metastasis and survival may be crucial.
Matrix metaloproteinases
Since MMPs are present within LAM lesions [49,50],
doxycycline (an MMP inhibitor that affects growth and
migration of neoplastic cells, angiogenesis, lymphangio-
genesis, and smooth muscle cell growth [51,52]) could
also be a therapeutic alternative. Recently, it was reported
that doxycycline therapy decreased urinary MMP levels
and improved lung function in a patient with LAM [53].
A double-blind placebo-controlled clinical trial is
planned at the University of Nottingham, UK (Simon




reductase inhibitors that may inhibit both rapamycin-
sensitive and rapamycin-insensitive mechanisms of
tuberin-null cell growth [54]. Indeed, statins block the
growth of Tsc2
−/− mouse embryo fibroblasts and ELT3
smooth muscle cells [54]. Statins did not, however,
decrease cystadenoma size in Tsc2
+/− mice [55]. Further-
more, therapeutic success with statins was not observed
in TSC, and no correlation between statin use and
angiomyolipoma response to sirolimus in patients with
TSC or sporadic LAM was observed [18]. In a retro-
spective study, the rate of decline in lung diffusion for
patients on statins was greater than that of their matched
controls [56].
Interferon, vascular endothelium growth factors, and
cyclin-dependent kinase 2 inhibitors
The combination of rapamycin and interferon (IFN)-g
was not more effective than rapamycin alone against
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+/− mice [57]. IFN-b,
which is expressed in LAM tissues and LAM cell cultures,
attenuated proliferation of LAM-derived and Tsc2-null
ELT3 cells, but this effect was potentiated by rapamycin
[58]. In a subcutaneous Tsc2
−/− tumor mouse model,
sorafenib, a vascular endothelial growth factor (VEGF)
receptor inhibitor, and sirolimus together increased
survival and decreased tumor volume more effectively
than sirolimus alone [57].
Other potential therapeutic options for LAM are CDK2
inhibitors [59,60]. Tuberin negatively regulates the
activity of CDK2, binding to the CDK inhibitor p27
(a major regulator of cell cycle progression), preventing
its degradation, and thereby increasing the amount of
p27 bound to CDK2. In tuberin-negative cells, p27 is
degraded and delocalized to the cytoplasm [59,60]. This
results in lack of inhibition of CDK activities in the cell
nucleus by p27. Therefore, inhibitors of CDK2, such as
roscovitine, a new potential anti-cancer agent [61], could
perhaps have a role in the therapy of LAM.
Pneumothorax
The highest incidence of pneumothorax among patients
with chronic lung diseases occurs in LAM, with multiple
recurrent pneumothorax occurring in 70% of patients
[1,62]. Generally, cyst size parallels the incidence of
pneumothorax; a higher incidence of pneumothorax is
seen in patients with larger cysts [62,63]. Furthermore,
pneumothoraces are associated with faster decline in
lung function in patients with mild disease [62,63].
In general, small pneumothoraces can be treated con-
servatively or, if they do not resolve, by closed
thoracostomy. If air leak persists, the lung does not
expand, or the pneumothorax recurs, chemical or
surgical pleurodesis by video-assisted thoracoscopy is
recommended [64]. Because of the high rate of
pneumothorax recurrence in LAM, pleurodesis at the
time of initial pneumothorax occurrence is recom-
mended [64]. Talc pleurodesis is the most effective
but may result in unwanted fibrothorax that can
complicate removal of the lung at the time of transplan-
tation [64].
Lymphangioleiomyomas, chylothorax, and ascites
Lymphatic involvement in LAM occurs in the posterior
mediastinum and in retroperitoneal and pelvic areas and
includes lymphadenopathy and lymphangioleiomyomas
[65]. Thoracic and abdomino-pelvic lymphangioleiomyo-
mas are observed in 16-21% of patients with LAM. On
computed tomography scans, tumors appear as well-
circumscribed masses of variable dimensions, comprising
a wall and a central fluid-rich region (Figure 1b) [65].
These tumor masses are probably caused by the
proliferation of LAM cells, leading to compression or
obstruction of lymphatic vessels and chylous effusions.
Of importance in differentiating lymphangioleiomyo-
mas from abdominal malignancies is the fact that
lymphangioleiomyomas exhibit a diurnal variation in
size [66,67].
Serum VEGF-D, a lymphangiogenic factor, is increased in
the serum of patients with LAM compared with normal
individuals and appears to be a measure of lymphatic
involvement in LAM [68-70]. Lymphangioleiomyomas
may cause pain, neuropathy, abdominal bloating,
urinary frequency, and edema, suggesting a lymphopro-
liferative disease [65,71-73]. Surgical resection of lym-
phangioleiomyomas is not recommended for standard
care as it may lead to lymphatic leakage, chylothorax,
and ascites.
Chylous effusions, including pleural effusions, are
particularly difficult to treat [74,75]. Low-fat diet with
medium-chain triglycerides and therapeutic thoracent-
esis should be attempted initially, however, most
patients require pleurodesis [75]. After pleurodesis, a
low-fat diet with medium-chain triglycerides is
recommended.
A pleuro-peritoneal or peritoneal-venous shunt may be
considered for the treatment of chylothorax or ascites
when the effusions are disabling and cause mechanical/
nutritional problems, but little experience with these
therapeutic modalities in LAM has been reported
[76,77]. Treatment with somatostatin and octreotide
may be considered for those patients with recurrent
pleural effusions or disabling ascites. Treatment with
these agents produced a successful reduction in chylous
effusions, chyluria, ascites, and peripheral lymphedema
in other clinical settings, such as idiopathic congenital
chylothorax, lymphoma, traumatic lymphatic injury,
and yellow nail syndrome [78-80]. Anti-VEGF-D thera-
pies may eventually become the best therapeutic option
for the treatment of these lymphatic disorders.
Angiomyolipomas
Angiomyolipomas of less than 4 cm in diameter are well
tolerated and are usually associated with well-preserved
renal function (Figure 1c). The principal complication of
larger angiomyolipomas is bleeding, which may cause
flank pain and bloody urine [81-83]. In this setting,
embolization of the tumor, rather than surgery, is
recommended to preserve kidney function. Intractable
pain is also an indication for selective embolization of
the tumor [81,82]. Prophylactic embolization can be
undertaken in patients who have large angiomyolipomas
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favoring this approach is still lacking [83]. Not infre-
quently, the blood supply of these tumors is complex,
comprising abnormal aberrant vasculature that may
prevent successful and safe arterial embolization. If
surgical therapy is being considered, all efforts should
be made to preserve the kidney [83].
Implications for clinical practice
In the last 10 years, there has been great progress in
understanding the natural history of LAM, its pathogen-
esis, and the biology of the LAM cell. Progress in therapy,
however, has come slowly. Despite a probable role of
estrogens in the pathogenesis of LAM, there is currently
no evidence that suppression of estrogen secretion by
oophorectomy or GnRH analogs or treatment with
progesterone is effective in LAM. New treatments based
on inhibition of the MAPK/ERK kinase pathway may be
proven to be effective. At present, inhibitors of regulators
of cell proliferation, specifically mTOR inhibitors such as
sirolimus or everolimus, appear to be the most promis-
ing therapeutic agents, although significant toxicity
associated with long-term therapy could be a major
problem. As a role of lymphangiogenesis and VEGF-D in
the pathogenesis of LAM is recognized, it may be possible
(as in the case of vascular tumors and malformations)
to develop effective anti-lymphangionesis agents in
LAM. Although a number of drug trials are under way
to test some of these therapies (in particular, inhibition
of mTOR), more research to discover new treatments
is warranted. As in cancer, the combination of several
agents may offer the best hope for effective therapy.
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